You are here

Press Release Archive

- DoveBid(R) to Conduct Online Auction for Pfizer Japan

(BUSINESS WIRE)--DoveBid, Inc., the leading global provider of capital asset auction and valuation services, announced today that it will conduct a series of biotech and pharmaceutical lab equipment sales via a featured online auction (FOA) for Pfizer Japan, Inc.’s laboratory located in Nagoya, Japan. Pfizer is a global leader in the development, production, marketing and sales of innovative healthcare products. The

- Pfizer to Appeal Canadian Federal Court Ruling on Lipitor Patent; Court's Decision Will Have No Immediate Commercial Impact

(BUSINESS WIRE)--Pfizer Inc said today it will appeal a Canadian Federal Court decision in favor of generic manufacturer Apotex in its challenge to a Pfizer patent covering Lipitor. The court denied Pfizer’s request to prevent Apotex from launching a generic version of Lipitor prior to the expiration of Pfizer’s enantiomer (calcium salt) patent in July 2010. The court’s decision has no immediate commercial

- Talking to a Doctor about Smoking Makes Quitting Easier - New Survey Reveals

(BUSINESS WIRE)--84 percent of ex-smokers who consulted with their doctor or another healthcare professional during their final successful quit attempt believe that giving up would have been more difficult if they had tried to quit alone – according to the results of a new European survey announced today.(1) The survey, which investigated the attitudes of nearly 1,000 ex-smokers on smoking and smoking cessation, revealed that 74 percent

- Pfizer Inc Announces Completion of the Tender Offer Relating to Outstanding Shares of Coley Pharmaceutical Group, Inc.

(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that it has completed the cash tender offer to purchase all of the outstanding shares of common stock of Coley Pharmaceutical Group, Inc. (Nasdaq:COLY). The tender offer expired, as scheduled, at midnight, Eastern time, on Friday, December 28, 2007. The offer was not extended. A total of 24,050,054 shares of Coley common stock were validly tendered and not withdrawn prior to the

- Pfizer Receives Approvable Letter from FDA for Dalbavancin

(BUSINESS WIRE)--Pfizer Inc today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) issued for dalbavancin HCl, Pfizer’s once-weekly two-dose antibiotic under FDA review for the treatment of adult patients with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The FDA recently published a draft guidance

- Pfizer Statement on Results of Comparative Analysis of Tropism Assays

(BUSINESS WIRE)--Pfizer Inc recently conducted a comparative analysis of the tropism assays TrofileTM, provided by Monogram Biosciences, and SensiTropTM, provided by Pathway Diagnostics. This analysis of 100 treatment experienced patient samples showed that the SensiTrop results were discordant with the results obtained using Trofile, which was used and clinically validated in the SelzentryTM (maraviroc) clinical trials

- Pfizer to Acquire CovX to Extend Biotherapeutics Investment

(BUSINESS WIRE)--Pfizer Inc announced today it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizer’s biologic portfolio. “The acquisition of CovX is a further step in Pfizer’s strategy to acquire and identify new product candidates

- Pfizer Inc Clears Antitrust Review for Acquisition of All Outstanding Shares of Coley Pharmaceutical Group, Inc.

(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired, and that it has received clearance from the Federal Cartel Office of Germany (FCO), in each case in connection with its offer to purchase all of the outstanding shares of common stock of Coley Pharmaceutical Group, Inc. (Nasdaq:COLY). Expiration of the waiting period under

- Pfizer Declares a 32-Cent First Quarter, 2008, Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent first–quarter, 2008, dividend on the company’s common stock, payable March 4, 2008, to shareholders of record at the close of business on February 8, 2008. Pfizer increased the dividend by approximately 10 percent from 29 cents to 32 cents per share as part of the Company’s continued commitment to enhancing shareholder return

- Pfizer Inc Commences Tender Offer for All Outstanding Shares of Coley Pharmaceutical Group, Inc.

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced the commencement of its cash tender offer for all outstanding shares of common stock of Coley Pharmaceutical Group, Inc. (Nasdaq:COLY) for $8.00 per share. The tender offer is being made pursuant to an Offer to Purchase, dated November 30, 2007, and in connection with the Agreement and Plan of Merger, dated November 15, 2007, by and among Pfizer, Corvette Acquisition Corp., an indirect

- Pfizer Invites Public to View and Listen to Webcast of November 30 Analyst Meeting in Hong Kong

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Friday, November 30, at 12:00p.m. Hong Kong Time (Thursday, November 29, at 11:00p.m. Eastern Daylight Savings Time). The analyst meeting will include a presentation by Dr. Martin Mackay, President, Pfizer Global Research and Development. To view and listen to the webcast, visit our

- Pfizer to Acquire Coley Pharmaceutical Group


- Pfizer and Nektar Reach Agreement on Exubera(R)

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Nektar Therapeutics (NASDAQ: NKTR) announced today that the two companies have resolved all outstanding contractual issues in connection with Exubera® and Nektar’s innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development. Under the terms of the agreement, Nektar will receive a one-time payment of $135 million from

- Lipitor Provides Greater Benefit Compared to simvastatin in Patients with a History of Heart Attacks Who Have Had Subsequent Cardiovascular Events

(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) was more effective than simvastatin (20 mg–40 mg) in reducing the risk of multiple cardiovascular events in patients with a history of heart attacks in the Incremental Decreases through Aggressive Lipid Lowering (IDEAL) clinical trial. Cardiovascular events included heart attack, stroke, and cardiac revascularization

- Post-Stroke Patients Treated with Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function

(BUSINESS WIRE)--Pfizer announced today that post-stroke or mini-stroke patients treated with Lipitor® (atorvastatin calcium) Tablets 80 mg had stabilization or improvement in kidney function. These results were demonstrated in patients with or without chronic kidney disease, metabolic syndrome or type 2 diabetes. This post-hoc analysis of the landmark Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study,

- New Lipitor Data Analyses from Landmark Ideal and SPARCL Trials to Be Presented at Upcoming Annual Scientific Sessions of the American Heart Association

(BUSINESS WIRE)--Pfizer announced today that new data regarding the cardiovascular and kidney function effects of Lipitor® (atorvastatin calcium) Tablets will be presented next week at the Annual Scientific Sessions of the American Heart Association. SPARCL Trial A new post-hoc analysis (planned after the study completed) of the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study looked

- Pfizer to Appeal German Court Decision in Lipitor Patent Case; Company Notes That Ruling Has No Immediate Commercial Impact

(BUSINESS WIRE)--Pfizer Inc said today that the Federal Patent Court in Munich, Germany has revoked the company’s patent covering atorvastatin calcium, the active ingredient in Lipitor. The patent at issue in the lawsuit (EP 409,281) expires in July 2010. The decision — which resulted from a patent challenge by generic manufacturers Ranbaxy Laboratories Limited and Basics GmbH — has no immediate commercial


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.